BPMX BioPharmX Corp. gains 67% Feb 19, 2021

BioPharmX Corporation, a specialty pharmaceutical company, focuses on the development of novel drug delivery products for women's health and dermatology markets. The company offers prescription and over-the-counter (OTC) products in oral, topical, and injectable forms. It provides VI2OLET iodine, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort and for the alleviation of symptoms of fibrocystic breast condition (FBC). The company's clinical-stage product candidates include BPX03, a molecular iodine tablet for the treatment of benign breast pain associated with FBC and cyclic mastalgia; and BPX01, a topical antibiotic for the treatment of acne. It serves pharmaceutical companies; physician's practices, including obstetricians and gynecologists, dermatologists, and general practitioners; and retail customers through retail sales channels and/or pharmacy outlets. The company has collaboration and licensing agreement with Iogen LLC for the development of molecular iodine products; and collaboration and supply agreement with NuTech Medical, Inc. to develop products in the field of dermatology. BioPharmX Corporation is headquartered in Menlo Park, California.http://www.priceseries.com/trade/BPMX-BioPharmX-Corp-stock-gains-67-percent-a-Trade-Record-by-priceSeries-2021020320210219.html